Industry leader in hyperthermic chemotherapy leverages its clinical knowledge assets with clinivation’s Patient Data Registry solution.
Framingham, MA, March 28, 2002 – clinivation, Inc. announced today that ViaCirq, Inc. has selected clinivation’s patient data registry solution.
“ViaCirq is clearly the industry leader in hyperthermic chemotherapy systems for advanced abdominal and thoracic cancer therapy,” said Joseph Kozikowski, M.D., clinivation’s Chief Executive Officer. “We are pleased that ViaCirq’s senior management has selected clinivation to help maximize their return on their clinical knowledge assets in the treatment of advanced GI, ovarian, thoracic and other cancers,” he continued.
Clinivaton’s turnkey patient data registry solution delivers total infrastructure and support for achieving real-time visibility of product clinical performance, HIPAA compliance, and maximizing ROI of prospective and legacy data.
About ViaCirq, Inc.
ViaCirq, Inc., the developer and marketer of the ThermoChem™ HT System, which delivers intraperitoneal hyperthermia, has standardized the procedure, enabling other medical institutions to provide this potentially life-extending treatment. The ThermoChem HT System is currently being used by 13 medical centers nationwide.
BICO, Inc. has its corporate offices in Pittsburgh and is involved in the development and manufacture of biomedical devices and environmental solutions. BICO’s subsidiary, ViaCirq, Inc., also located in Pittsburgh, PA, is committed to developing, manufacturing and marketing leading-edge hyperthermia products and services of the highest quality and value.
For more information about ViaCirq, Inc., visit the company’s web site a www.viacirq.com
